Thermo Fisher Scientific Completes $4.1 Billion Acquisition of Solventum's Purification & Filtration Business

Event Registration in Beijing and Shanghai:The 3rd Global Surgical Robotics Conference2025 Medical Device R&D Innovation Forum

September 2, 2025Solventum（NYSE: SOLV）Announced that it has completed itsPurification & Filtration (P&F) BusinessIn$4.1 billion (approximately RMB 29.2 billion)Sold toThermo Fisher Scientific（NYSE: TMO）The transaction. This transaction is not only the most significant asset adjustment for Solventum since its independent listing, but also a crucial step for Thermo Fisher Scientific in the global integration of the bioprocessing industry chain. For both parties, this deal is both the result of capital operations and a reflection of strategic choices, which will have a profound impact on the global healthcare and life sciences industry landscape.

1. $4.1 Billion Deal Completed: Process and Details

The deal was initially agreed upon on February 25, 2025, received approval from the European Commission on July 15, and was ultimately completed on September 2, aligning with the previously set expectation of "closing by the end of 2025." According to the announcement, the total transaction amount is$4.1 billionAfter deducting customary adjustments, Solventum is expected to receive approximately $3.4 billion in net proceeds.

In terms of fund usage, Solventum will primarily use the proceeds to repay debts, thereby optimizing its capital structure and enhancing financial flexibility. This also provides room for future organic growth (new product development, market expansion) and inorganic growth (potential mergers and acquisitions). To ensure a smooth business transition, Solventum will continue to provide certain manufacturing and distribution services to Thermo Fisher during the transition period following the completion of the transaction.

Capital Markets React Positively to Deal News. On the day the agreement was announced in February this year, Solventum's share price rose by about 10%, closing at $83.96; and as of September 2, the share price was $71.82, which although had retreated somewhat, the market widely endorsed its "streamlined focus" strategic logic. Thermo Fisher's share price remained basically stable, reflecting that investors had fully anticipated its long-term M&A strategy.

2. Positioning and Value of P&F Business

The purification and filtration business being sold is an important part of Solventum's original 3M healthcare segment. This business has applications in multiple industries, including medical technology, biopharmaceuticals, microelectronics, and food and beverage. Particularly in the field of biopharmaceutical manufacturing, its filtration and membrane technologies are crucial for ensuring the efficiency and purity of pharmaceutical production.

In 2024,P&F business revenue is approximately 1 billion US dollars,With approximately 2,500 employees, the company operates across the Americas, Europe, the Middle East, Africa, and the Asia-Pacific region. Although its business scale is not the largest within Solventum's overall portfolio, its "indispensability" in the bioprocessing sector makes it highly attractive to industry giants like Thermo Fisher Scientific.

For Thermo Fisher, this business is highly complementary to its Life Sciences Solutions segment, particularly in the配套环节 of cell culture media and single-use technologies, where significant synergies can be formed. According to Thermo Fisher's projections, the P&F business is expected to generate approximately $125 million in revenue and cost synergies over the next five years, achieving a double-digit internal rate of return in the long term.

III. Solventum's Strategic Adjustment and Financial Optimization

Solventum was spun off from 3M Group in April 2024 to become an independent publicly listed company, with its headquarters located in St. Paul, Minnesota. The top priority after becoming independent is to optimize the asset portfolio and improve capital efficiency.

The sale of the P&F business is considered the third phase of Solventum's "three-phase transformation plan," with the core objective being:

• Focusing on core businesses such as medical devices and health information technology;

• Reduce leverage ratio and improve capital structure;

• Enhance profitability and market valuation.

Financial data also supports this logic. In the updated full-year 2025 financial guidance, the company raised its adjusted earnings per share (EPS) from the previous $5.80-$5.95 to $5.88-$6.03, primarily benefiting from a decrease in interest expenses (from $450 million to $400 million), which offset the revenue impact of the P&F business divestiture. The operating profit margin is expected to reach the upper limit of 20% to 21%, indicating an improvement in operational efficiency.

At the shareholder level, Trian Fund Management, an activist investor holding approximately 4.9% of Solventum's shares, has been pushing the company to reduce debt and focus on its core business. The completion of this transaction is a response to shareholder demands and market expectations.

4. Thermo Fisher's Acquisition Logic

As a global leader in scientific services,Thermo FisherTo achieve revenue exceeding $40 billion in 2024, with the Life Sciences Solutions segment generating $9.6 billion.The acquisition of Solventum's P&F business is both a move to consolidate market share and a strategy to expand business depth.

In the bioprocessing market, Thermo Fisher has long been in competition with rivals such as Danaher and Repligen. Through this acquisition, Thermo Fisher has further strengthened its capabilities in filtration technology, achieving full-process coverage especially in the biopharmaceutical production segment. From upstream cell culture media, to midstream filtration and membrane processing, to downstream analytics and testing, Thermo Fisher's product portfolio is becoming increasingly comprehensive.

In the short term, the acquisition is expected to have a slight dilutive effect on the company's adjusted EPS for 2025 (approximately $0.06), but excluding financing costs, it will increase by about $0.28. In the long term, as synergies are realized and integration progresses, profitability is expected to steadily improve.

5. Enlightenment at the Industry Level

From a broader perspective, this $4.1 billion deal reflects several major trends in the healthcare and biotechnology industries:

First,M&A Integration Continues to AccelerateAs the global biopharmaceutical industry enters a stage of rapid development, the strategic importance of key areas such as filtration, membrane technology, and single-use consumables has become increasingly prominent. Large multinational companies secure these core areas through acquisitions, building "one-stop solutions."

Secondly,Divestiture of Non-Core Assets Becomes the NormFor a newly independent company like Solventum, focusing on areas of strength and optimizing the financial structure are more important than blind expansion. This also provides a reference for China's domestic medical device companies: during the industrial upgrading process, how to allocate capital reasonably and concentrate efforts to make breakthroughs in key sectors is the key to enhancing competitiveness.

Third,The capital market has a higher recognition of the focus strategy.Solventum's stock price rose 10% after the deal was announced, a clear endorsement by the market of its "streamlining transformation." Meanwhile, Thermo Fisher's steady performance reflects investors' confidence in its long-term M&A integration capabilities.

In today's increasingly competitive medical and biotechnology industries,Companies either form deep barriers by focusing, or achieve full-chain coverage through mergers and acquisitions.。This is not only the choice of multinational giants, but also a strategic decision that Chinese medical technology companies may have to face in the process of globalization.